Genmab A/S (NASDAQ:GMAB) Raised to Strong-Buy at BNP Paribas Exane

Genmab A/S (NASDAQ:GMAB) was upgraded by research analysts at BNP Paribas Exane from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Other analysts have also issued reports about the stock. Wells Fargo & Company assumed coverage on shares of Genmab A/S in a research note on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective for the company. Truist Financial raised shares of Genmab A/S to a “strong-buy” rating in a research note on Wednesday, March 25th. Guggenheim lowered their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday. Finally, Wolfe Research assumed coverage on shares of Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.36.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $26.98 on Wednesday. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86. The stock’s fifty day moving average price is $27.73 and its 200-day moving average price is $30.27. The firm has a market cap of $17.33 billion, a P/E ratio of 17.41, a P/E/G ratio of 1.24 and a beta of 0.97. Genmab A/S has a 12 month low of $18.89 and a 12 month high of $35.43.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 18th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. On average, equities research analysts expect that Genmab A/S will post 1.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its holdings in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares in the last quarter. NewEdge Advisors LLC increased its holdings in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares in the last quarter. Brown Brothers Harriman & Co. increased its holdings in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares in the last quarter. Finally, Founders Capital Management increased its holdings in shares of Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.